Market revenue in 2021 | USD 399.2 million |
Market revenue in 2028 | USD 534.8 million |
Growth rate | 4.3% (CAGR from 2021 to 2028) |
Largest segment | Accu-chek inform ii |
Fastest growing segment | CareSens Expert Plus |
Historical data | 2016 - 2020 |
Base year | 2021 |
Forecast period | 2022 - 2028 |
Quantitative units | Revenue in USD million |
Market segmentation | I-STAT, CareSens Expert Plus, Accu-Chek Inform II, StatStrip, HemoCue |
Key market players worldwide | Roche Holding AG ADR, Abbott Laboratories, Nova Biomedical, Bayer AG, Danaher Corp |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to network point-of-care glucose testing market will help companies and investors design strategic landscapes.
Accu-chek inform ii was the largest segment with a revenue share of 48.07% in 2021. Horizon Databook has segmented the U.S. network point-of-care glucose testing market based on i-stat, caresens expert plus, accu-chek inform ii, statstrip, hemocue covering the revenue growth of each sub-segment from 2016 to 2028.
Large population at high risk of diabetes in the U.S. is a key factor contributing to the dominance of the U.S. in North America POC glucose testing market in 2019. Diabetes was reported to be 7th most common cause of death in the U.S. with more than 30.9 million Americans suffering from the disease in 2019.
Presence of government organizations focusing on creating awareness regarding diabetes and glucose testing products available in the market has propelled the market growth in the country.
For instance, American Heart Association, American Diabetes Association, and Pan American Health Organization are especially involved in such initiatives. According to International Diabetes Federation, the prevalence rate of diabetes is 13.3% of the total population.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. network point-of-care glucose testing market , including forecasts for subscribers. This country databook contains high-level insights into U.S. network point-of-care glucose testing market from 2016 to 2028, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account